实时全球研报
2Q26 Recap: Pass-Through Margin Dynamics Overshadow Strong RFP Activity; Remain Neutral
研报英文原文证据摘录
2Q26 Recap: Pass-Through Margin Dynamics Overshadow Strong RFP Activity; Remain Neutral
J P M O R G A N North America Equity Research
30 July 2026
ICON Plc Neutral
ICLR, ICLR US
2Q26 Recap: Pass-Through Margin Dynamics Price (29 Jul 26):$178.18
Overshadow Strong RFP Activity; Remain Neutral ▲Price Target (Dec-27):$165.00 Prior (Dec-26):$155.00
ICLR reported 2Q26 results that landed above the Street on both the top and bottom
lines (revenue of $2.06B vs. Street of $2.01B and adj. EPS of $2.56 vs. Street of Life Science Tools & Diagnostics
$2.51) and the company reiterated top and bottom line 2026 guidance. The story Casey Woodring AC
of the quarter was the increased level of pass-throughs that drove the revenue beat (1-212) 622-9074
as well as elevated bookings numbers, with ICLR posting a B2B of 1.51 and direct casey.woodring@jpmchase.com
fee B2B of 1.20, the latter of which came in-line with the company’s expectations Marta Nazarovets Zaremba
(as we noted last quarter) albeit below the >1.3 seen in 1Q. The increased pass- (1-212) 622-6046
marta.zaremba@jpmchase.com
through revenue in the quarter drove a slight adj. EBITDA margin miss vs. our
Jaden Rismay
estimates (ICLR reported adj. EBITDA margin of 15.9% vs. JPMe of 16.0%), and
(1-212) 622-8479
management indicated that it believes it could see increased pass-through revenue jaden.rismay@jpmchase.com
in 2026 relative to prior expectations, which could drive revenue to the higher end J.P. Morgan Securities LLC
of the range but adj. EBITDA margin lower (more detail on this below).
Management made it clear that the it is not sacrificing direct fee revenue when
adding more pass-throughs (pointing investors to the operating profit dollar Quarterly Forecasts (FYE Dec)
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器